RESOLUTION OF THE PANEL OF EXPERTS ON «THE PHARMACEUTICAL PROVISION OF PSORIATIC ARTHRITIS PATIENTS WITH THE TARGETED SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG APREMILAST AS TABLETS»
.
Saved in:
| Format: | Article |
|---|---|
| Language: | Russian |
| Published: |
IMA PRESS LLC
2018-05-01
|
| Series: | Научно-практическая ревматология |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/2535 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical experience with apremilast for psoriatic arthritis
by: E. Yu. Loginova, et al.
Published: (2018-09-01) -
Impact of Delay of Treatment With Disease‐Modifying Antirheumatic Drugs in Psoriatic Arthritis: The CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
by: Philip J. Mease, et al.
Published: (2025-06-01) -
THE EFFICACY AND SAFETY OF THE NEW DRUG APREMILAST FOR THE TREATMENT OF PSORIASIS AND PSORIATIC ARTHRITIS
by: Yu. L. Korsakova, et al.
Published: (2016-12-01) -
The efficacy and safety of apremilast in patients with psoriatic arthritis concurrent with comorbidity in clinical practice
by: E. Yu. Loginova, et al.
Published: (2019-07-01) -
Biological Disease-Modifying Antirheumatic Drugs Decrease Uric Acid Levels in the Sera of Patients with Psoriatic Arthritis
by: Dijana Perković, et al.
Published: (2025-02-01)